Unprecedented results against a stubbornly hard-to-treat cancer are boosting optimism that other challenging tumors will be ...
Mirvetuximab soravtansine (also known as Elahere) is the first new drug to be approved for hard-to-treat ovarian cancer in ...
In the study, patients taking the drug lived longer compared to those undergoing chemotherapy. "This study showed that they ...
Targeted drug shows promise for people with advanced bowel cancer in early trial - One patient taking part in the trial said ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results